August 11, 2022

MediPharm Labs Sets Date to Report Second Quarter 2022 Financial Results

BARRIE, August 11, 2022 /CNW/ -MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the“Company”) a pharmaceutical company specialized inprecision-based cannabinoids, is pleased to announce it will releasesecond quarter financial resultsfor the three and six month period ended June 30,2022 before marketsopen on Monday, August 15, 2022.

MediPharm’s executive management team will also host a conference calland audio webcast on Monday, August 15, 2022, at 8:30 a.m. eastern time to discuss the Company’sfinancial results and outlook.

Audio Conference Call Dial in Details:

Toll-free number: 1(888) 330-2454 / International number: 1 (240) 789-2714 / Conference ID: 4921762

Participants are asked to dial in approximately 15 minutes before the start of the call.

Audio Webcast:

An audio webcast will be available in the Events section of the MediPharmwebsite https://www.medipharmlabs.com/investors or by visiting the following link here.

For those who are unable to participate on the live conference call orwebcast, a replay will be available approximately one hour after completion of the call.

About MediPharm Labs Corp.

Founded in 2015,MediPharm specializes in the development and manufacture of purified,pharmaceutical-quality cannabis concentrates, API and advanced derivativeproducts utilizing a Good Manufacturing Practices certified facility with ISOstandard-built clean rooms. MediPharm has invested in an expert, researchdriven team, state-of-the-art technology, downstream purification methodologiesand purpose-built facilities with five primary extraction lines for delivery ofpure, trusted and precision-dosed cannabis products for its customers. Throughits wholesale and white label platforms, MediPharm formulates, develops(including through sensory testing), processes, packages and distributescannabis extracts and advanced cannabinoid-based products to domestic andinternational markets.

In 2021,MediPharm received a Drug Establishment Licence from Health Canada, becomingthe only company in North America to hold a domestic Good ManufacturingPractices licence for the extraction of natural cannabinoids. The Companycarries out its operations in compliance with all applicable laws in thecountries in which it operates.

For further information, please contact:

Investor Relations

Telephone: +1 416-913-7425

Email: investors@medipharmlabs.com

Website: www.medipharmlabs.com

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and“forward-looking statements” (collectively, “forward-looking statements”) within the meaning of theapplicable Canadian securities legislation. All statements, other thanstatements of historical fact, areforward-looking statements and are based on expectations, estimates andprojections as at the date of this newsrelease. Anystatement that involves discussions with respect to predictions, expectations,beliefs, plans, projections, objectives, assumptions, future events orperformance (often but not always using phrases such as "expects", or"does not expect", "is expected", "anticipates"or "does not anticipate", "plans", "budget","scheduled", "forecasts", "estimates","believes" or "intends" or variations of such words andphrases or stating that certain actions, events or results "may" or"could", "would", "might" or "will" betaken to occur or be achieved) are not statements of historical fact and may beforward-looking statements. Forward-lookingstatements are necessarily based upon a number of estimates and assumptionsthat, while considered reasonable, are subject to known and unknown risks,uncertainties, and other factors which may cause the actualresults and future events to differ materially from those expressed or implied by such forward-looking statements. Such factorsinclude, but are not limited to: general business,economic, competitive, political and social uncertainties; the inability ofMediPharm to obtain adequate financing; the delay or failure to receiveregulatory approvals; and other factors discussed in MediPharm’s filings,available on the SEDAR website at www.sedar.com. There can be noassurance that such statements will prove tobe accurate, as actual results and future events could differ materially fromthose anticipated in such statements. Accordingly,readers should not place undue reliance on the forward-looking statements andinformation contained in this news release.Except as requiredby law, MediPharmassumes no obligation to update the forward-looking statements of beliefs, opinions,projections, or other factors, should they change.